| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 6.61 | -0.07 (-1.05%) | 2.27 - 7.30 | 181.4 thousand (Below Avg) |
Market data as of 1:37PM 05/20/13. Quotes are delayed by at least 15 min.
| Open | 6.65 |
|---|---|
| Previous Close | 6.68 |
| Day's Range | 6.60 - 6.93 |
| Market Cap | 246.1M |
| Avg Volume (10 Day) | 355.8K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.49 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
PR Newswire - Thursday 05/16/2013 3:20 PM ET
AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
PR Newswire - Wednesday 05/08/2013 4:05 PM ET
AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
PR Newswire - Friday 05/03/2013 7:30 AM ET
AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
PR Newswire - Thursday 05/02/2013 7:30 AM ET
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
PR Newswire - Wednesday 04/24/2013 7:30 AM ET
| ACRX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 114.49% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.65 | |
| LT Debt/Equity | 0.30 | |
| Earnings Yield | -- | |
| Price/Sales | 82.78 |
| Company | Last | Change |
|---|---|---|
| Regulus Therapeutics Inc | 7.00 | -1.41% |
| Star Scientific Inc | 1.35 | +5.47% |
| SIGA Technologies Inc | 3.61 | +0.84% |
| Ampio Pharmaceuticals Inc | 4.81 | -4.37% |
| Raptor Pharmaceutical Corp | 6.41 | +9.95% |
Data is delayed by at least 15 min.